This review provides an overview of current and novel pharmacological treatments for stable coronary artery disease aimed at preventing myocardial infarction and reducing angina symptoms.
Offers clinicians a current synthesis of anti-ischemic options in stable CAD; leaves open optimal integration of novel agents.
Coronary artery disease is the leading cause of death in the world. Despite the increasing success of conventional medical therapies and the continued development and improvement of percutaneous coronary intervention, a significant number of patients with ischemic heart disease and angina pectoris cannot be successfully managed. There are two major purposes in the treatment of stable angina. The first is to prevent myocardial infarction and death and thereby, increase the quantity of life. The second is to reduce symptoms of angina and the frequency and severity of ischemia, which should improve the quality of life. Antiischemic agents, including beta-blockers, nitrates and calcium channel blockers, remain the mainstay in the prevention of angina. Also new pharmacological options for refractory angina, metabolic agents, and vasodilator therapies are adding to the armamentarium to prevent and treat angina. This review will summarize current recommended pharmacological approachesof stable coronary artery disease, with a focuson novel therapies.
No takes yet. Share an insight, caveat, or question.
Tekin et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: